Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Sinto Chirackal, Gregory Ahmann, Esteban Braggio et al. Nov 03, 2025 pp. 2139-2139 10.1182/blood-2025-2139

Abstract Background: Proteasome inhibitors (PIs) are a cornerstone of multiple myeloma (MM) therapy, exploiting the high rate of immunoglobu...

Myelodysplastic syndrome in Tanzania; The current status of management

Eunice Shija, Koga Luhulla, primus ewald et al. Nov 03, 2025 pp. 7397-7397 10.1182/blood-2025-7397

Abstract Introduction Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by ineffective hematopoiesis, peripheral cyt...

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Pierre Sesques, Guillaume Manson, Guillaume Cartron et al. Nov 03, 2025 pp. 956-956 10.1182/blood-2025-956

Abstract Background: Relapse after CAR T-cell therapy in large B-cell lymphoma (LBCL) is associated with poor prognosis, lacking a clear sal...

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Xuelin Dou, Chunrui Li, Aijun Liao et al. Nov 03, 2025 pp. 5819-5819 10.1182/blood-2025-5819

Abstract Background: Intravenous (IV) isatuximab plus pomalidomide and dexamethasone (Isa-Pd) is approved for treatment in patients with rel...

Unmasking the unknown: A case of bone marrow carcinomatosis with elusive primary

Sana Mulla, Ruqqiya Mustaqeem, Faiz Anwer Nov 03, 2025 pp. 6741-6741 10.1182/blood-2025-6741

“comparative outcomes of midline versus peripheral intravenous catheters: A systematic review and meta-analysis.”

Misbah Uddin, Muhammad Shaheer Bin Faheem, Sai Sushrutha Mudupula Vemula et al. Nov 03, 2025 pp. 7912-7912 10.1182/blood-2025-7912

Abstract Background: Intravascular catheters are indispensable to contemporary inpatient therapy and peripherally inserted central catheters...

Loss of endothelial mir-126 drives age-related reduction of hematopoietic activity

Dandan Zhao, Le Xuan Truong Nguyen, Xubo Gong et al. Nov 03, 2025 pp. 1392-1392 10.1182/blood-2025-1392

Abstract Aging hematopoietic stem cells (HSCs) expand but their functional capacity declines. To prioritize the relative contributions of in...

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Prajna Woonnimani, Amanda Bruegl, Haley Burns et al. Nov 03, 2025 pp. 7784-7784 10.1182/blood-2025-7784

Abstract Introduction: Allogeneic hematopoietic cell transplantation (alloHCT) survivors are at risk for secondary malignancies (SM), such a...

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)

Matthew Rees, Masa Lasica, Anna Kalff et al. Nov 03, 2025 pp. 4039-4039 10.1182/blood-2025-4039

Abstract Introduction: Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) in combination with...

Unequal outcomes: The role of institutional setting in the management of primary CNS lymphoma

Ysaith Orellana Ascencio, Supreet Kaur, Leyla Bojanini et al. Nov 03, 2025 pp. 4493-4493 10.1182/blood-2025-4493

Abstract Background: Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive non-Hodgkin lymphoma confined to the br...

Impact of oral eicosapentaenoic acid on veno-occlusive disease/sinusoidal obstruction syndrome onset prevention: Single-center retrospective analysis

Yuya Masuda, Yukihiro Miyazaki, Kento Mori et al. Nov 03, 2025 pp. 2413-2413 10.1182/blood-2025-2413

Abstract Introduction Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication following allogeneic hemato...

Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma

Malgorzata Nowicka, Wilfred Leung, Carmelo Carlo-Stella et al. Nov 03, 2025 pp. 5316-5316 10.1182/blood-2025-5316

Abstract Background: Glofitamab, a CD20-CD3 T-cell bispecific, has demonstrated high and durable complete responses (CR) in patients (pts) w...

Sodium-glucose cotransporter-2 inhibitors may modulate complement pathway activation in paroxysmal nocturnal hemoglobinuria

Asfand Yar Cheema, Mishaal Munir, Aashray Mandala et al. Nov 03, 2025 pp. 3200-3200 10.1182/blood-2025-3200

Abstract PNH is a bone marrow failure syndrome characterized by intravascular hemolysis and thrombotic proclivity. Complement inhibitors (CI...

From photosensitivity to cure: Hematopoeitic stem cell transplant for congenital erythropoeitic porphyria in a low-resource setting

Aamir Awan, Raheel Iftikhar, Tariq Ghafoor et al. Nov 03, 2025 pp. 7725-7725 10.1182/blood-2025-7725

Abstract Abstract: Congenital Erythropoeitic Porphyria is extremely rare autosomal recessive disorder caused by deficiency of uroporphyrin s...

Prevalence of iron deficiency anemia associated with malabsorption syndromes among African American women

Samreen Kidwai, Le Yen Ly Nguyen, Kalgi Vaghasiya et al. Nov 03, 2025 pp. 6472-6472 10.1182/blood-2025-6472

Abstract Introduction: Iron deficiency anemia (IDA) is one of the most prevalent blood disorders in the world, dispropor...

Endocrine adverse events following CAR-T cell therapies: A pharmacovigilance analysis in the real-world setting utilizing the faers database

Rushi Shah, Tanisha Vora, Dakshin Padmanabhan et al. Nov 03, 2025 pp. 7666-7666 10.1182/blood-2025-7666

Abstract Background: CAR-T cell therapies have transformed treatment for hematologic malignancies. While hematologic and cytokine-related to...

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Paolo Strati, Lei Feng, Luis Malpica et al. Nov 03, 2025 pp. 3571-3571 10.1182/blood-2025-3571

Abstract Introduction . We have recently completed a phase I trial of evorpacept (formerly known as ALX148), a novel high-affinity signal reg...

Phase II, single-arm, open-label, multicenter study: Efficacy of adjunctive Bruton's tyrosine kinase inhibitor (BTKi) zanubrutinib and chimeric antigen receptor (CART) in aggressive B-cell non-hodgkins lymphoma (aNHL)

Reem Karmali, Carlos Galvez, Jane Winter et al. Nov 03, 2025 pp. 1010-1010 10.1182/blood-2025-1010

Abstract Background: Resistance to CART has been linked to T-cell exhaustion with suppressive effects on the tumor microenvironment (TME), r...

Feasibility of impementing pre-marital genetic counseling in kano, northern Nigeria using the cfir-eric model

Aisha Galadanci Akilu, Faisal Dankishiya, Sabiu Yarima et al. Nov 03, 2025 pp. 6228-6228 10.1182/blood-2025-6228

Abstract Background: Sickle cell disease (SCD) is an autosomal recessive disorder where premarital genetic counseling (PGC) and screening ca...

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

MacKenzie Mayo, Saumya Karne, Hyejeong Jang et al. Nov 03, 2025 pp. 7832-7832 10.1182/blood-2025-7832

Abstract Background: Allogenic hematopoietic stem cell transplantation (AHSCT) for myelofibrosis (MF) patients (pts) can involve several dis...

Successful first-line use of pemigatinib in myeloid/lymphoid neoplasm with FGFR1 rearrangement: Clinical insights

Christos Stafylidis, Eleni Variami, Eleftheria Lakiotaki et al. Nov 03, 2025 pp. 7321-7321 10.1182/blood-2025-7321

Abstract Introduction Myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1) comprise a...

Addressing psychological burden in patients newly diagnosed with lymphoma or myeloma: Patient perspectives on potential interventions

Andrew Ferrar, Angel Cronin, Hari Raman et al. Nov 03, 2025 pp. 2746-2746 10.1182/blood-2025-2746

Abstract Background: More than half of patients newly diagnosed with lymphoma or myeloma experience clinically significant anxiety or depres...

Shared decision making for immune thrombocytopenia (ITP) treatment: Data from the ITP natural history study registry

Taylor Bowles, Jennifer MacWhirter - DiRaimo, Kevin Won et al. Nov 03, 2025 pp. 3041-3041 10.1182/blood-2025-3041

Abstract Introduction: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder associated with an increased risk for bleeding. Vari...

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

Matthew Wieduwilt, Jun Yin, Oudom Kour et al. Nov 03, 2025 pp. 444-444 10.1182/blood-2025-444

Abstract Background: Older adults with newly diagnosed ALL treated with conventional chemotherapy have poor survival due to high rates of to...

The Mayo Clinic enterprise experience and outcomes of perioperative utilization of recombinant factor VIIa (rFVIIa, NovoSeven®)

Isabela Chang, Jill Adamski, Therese Kinard et al. Nov 03, 2025 pp. 4863-4863 10.1182/blood-2025-4863

Abstract Background: Recombinant activated factor VIIa (rFVIIa, NovoSeven®) is an FDA-approved medication for managing b...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page